Applications in accordance with U.S. Pharmacopoeia Methods
Applications of USP Standars using COSMOSIL columns in accordance with the conditon specfied in USP-PF(Pharmacopoeial Forum) online is available.
Drugs Alphabetical index
Amlodipine
| Monographs | Tests | Columns |
|---|---|---|
| 37(1) In-Process Revision Amlodipine Oral Suspension | Assay | 5CN-MS |
| 38(1) In-Process Revision Amlodipine and Benazepril Hydrochloride Capsules | Impurities | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Performance tests | 3C18-EB |
Amlodipine Besylate
| Monographs | Tests | Columns |
|---|---|---|
| 34(5) In-Process Revision Amlodipine Besylate | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Related compounds | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 36(2) In-Process Revision Amlodipine Besylate Tablets | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| Impurities | 5C18-MS-II | |
| 5C18-AR-II |
Amoxicillin
| Monographs | Tests | Columns |
|---|---|---|
| 36(4) In-Process Revision Amoxicillin and Clavulanate Potassium for Oral Suspension | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 36(4) In-Process Revision Amoxicillin and Clavulanate Potassium Tablets | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ |
Benazepril Hydrochloride
| Monographs | Tests | Columns |
|---|---|---|
| 38(1) In-Process Revision Amlodipine and Benazepril Hydrochloride Capsules | Impurities | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Performance Tests | 3C18-EB |
Chlorpheniramine Maleate
| Monographs | Tests | Columns |
|---|---|---|
31(2) Second Interim Revision Announcement: Chlorpheniramine Maleate Extended-Release
Capsules  |
Assay | 5C18-PAQ |
Chlorothiazide
| Monographs | Tests | Columns |
|---|---|---|
| 29(5) In-Process Revision Chlorothiazide | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Related compounds | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ |
Clavulanate Potassium
| Monographs | Tests | Columns |
|---|---|---|
| 34(6) In-Process Revision Clavulanate Potassium | Chromatographic purity (1) | 5C18-MS-II |
| Chromatographic purity (2) | 5C18-MS-II | |
| Assay (1) | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Assay (2) | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 36(4) In-Process Revision Amoxicillin and Clavulanate Potassium for Oral Suspension | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 36(4) In-Process Revision Amoxicillin and Clavulanate Potassium Tablets | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ |
Esomeprazole Magnesium
| Monographs | Tests | Columns |
|---|---|---|
| 35(3) In-Process Revision Esomeprazole Magnesium | Assay | 5C8-MS |
| Impurities | 5C8-MS | |
| 37(3) In-Process Revision Esomeprazole Magnesium Delayed-Release Capsules | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Impurities | 3C18-EB |
Gabapentin
| Monographs | Tests | Columns |
|---|---|---|
| 32(6) In-Process Revision Gabapentin | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 32(6) In-Process Revision Gabapentin Capsules | Assay | 5C8-MS |
| Dissolution | 5C8-MS | |
| Related compounds | 5C8-MS | |
| 34(4) In-Process Revision Gabapentin Tablets | Assay | 5C8-MS |
| Dissolution | 5C8-MS | |
| Related compounds | 5C8-MS |
Glimepiride
| Monographs | Tests | Columns |
|---|---|---|
| 33(3) In-Process Revision Glimepiride Tablets | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Dissolution | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Related compounds | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ |
Hydrochlorothiazide
| Monographs | Tests | Columns |
|---|---|---|
| 28(6) In-Process Revision: Hydrochlorothiazide |
Assay | 3C18-EB |
| Related compounds | 3C18-EB | |
| 34(6) In-Process Revision: Losartan Potassium and Hydrochlorothiazide Tablets
|
Assay | 5C8-MS |
| Related compounds | 5C8-MS | |
| Dissolution | 5C8-MS | |
| Uniformity of dosage units?Procedure for content uniformity | 5C8-MS | |
| 36(2) In-Process Revision Hydrochlorothiazide Capsules | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Impurities - Organic Impurities |
5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 28(6) In-Process Revision: Hydrochlorothiazide Tablets |
Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Related compounds | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 37(4) In-Process Revision Valsartan and Hydrochlorothiazide Tablets | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Impurities - Organic Impurities |
5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Dissolution - Chromatographic procedure | 5PE-MS |
Losartan Potassium
| Monographs | Tests | Columns |
|---|---|---|
| 34(3) In-Process Revision Losartan Potassium | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Chromatographic purity | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 34(6) In-Process Revision: Losartan Potassium and Hydrochlorothiazide Tablets
|
Assay | 5C8-MS |
| Related compounds | 5C8-MS | |
| Dissolution | 5C8-MS | |
| Uniformity of dosage units-Procedure for content uniformity | 5C8-MS | |
| 36(2) In-Process Revision Losartan Potassium Tablets | Assay | 5C8-MS |
| Uniformity of dosage units | 5C8-MS | |
| Impurities - Organic impurities |
5C8-MS |
Metformin Hydrochloride
| Monographs | Tests | Columns |
|---|---|---|
| 33(2) Second Interim Revision Announcement Metformin Hydrochloride Tablets | Dissolution - Test 3 | 5C18-MS-II |
| Assay | 5C18-AR-II | |
| 5C18-PAQ | ||
| 35(1) In-Prcess Revision Metformin Hydrochloride Extended-Release Tablets | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Chromatographic purity | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 35(6) In-Process Revision Glyburide and Metformin Hydrochloride Tablets | Assay (Metformin Hydrochloride) | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Organic impurities - Procedure 2: (Metformin Hydrochloride) | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ |
Omeprazole
| Monographs | Tests | Columns |
|---|---|---|
| 37(1) In-Process Revision Omeprazole Oral Suspention | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 37(5) In-Process Revision Omeprazole Delayed-Release Capsules | Assay | 5C8-MS |
| Performance Tests (Dissolution Test 1 - Acid resistance stage) |
5C8-MS | |
| Performance Tests (Dissolution Test 1 - Buffer stage) |
5C8-MS |
Pantoprazole
| Monographs | Tests | Columns |
|---|---|---|
| 35(4) In-Process Revision Pantoprazole Oral Suspension | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ |
Pantoprazole Sodium
| Monographs | Tests | Columns |
|---|---|---|
| 34(3) Third Interim Revision Announcement Pantoprazole Sodium | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Related compounds - Test 1 |
5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ |
Ramipril
| Monographs | Tests | Columns |
|---|---|---|
| 31(3) In-Process Revision Ramipril | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 35(4) In-Process Revision Ramipril Capsules | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Performance tests - Dissolution | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Performance tests - Uniformity of dosage units | 5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ |
Valsartan
| Monographs | Tests | Columns |
|---|---|---|
| 33(3) In-Process Revision Valsartan | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 37(3) In-Process Revision Valsartan Tablets | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Impurities - Organic Impurities |
5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| 37(4) In-Process Revision Valsartan and Hydrochlorothiazide Tablets | Assay | 5C18-MS-II |
| 5C18-AR-II | ||
| 5C18-PAQ | ||
| Impurities - Organic Impurities |
5C18-MS-II | |
| 5C18-AR-II | ||
| 5C18-PAQ |
